Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study

Clinical Chemistry and Laboratory Medicine

Volumn 54, Issue 2, 2016, Pages 275-283

  Harenberg, Job ^a   Du, Shanshan ^a   Wehling, Martin ^a   Zolfaghari, Shabnam ^a   Weiss, Christel ^a   Krämer, Roland ^a   Walenga, Jeanine ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anticoagulants; antithrombins; clinical chemistry tests; direct factor Xa inhibitors; plasma; point of care systems; serum; urine

Indexed keywords

APIXABAN; BLOOD CLOTTING FACTOR 10A; DABIGATRAN ETEXILATE; RIVAROXABAN; THROMBIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; CHROMOGENIC SUBSTRATE; DABIGATRAN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ARTICLE; ATRIAL FIBRILLATION; BLOOD ANALYSIS; CLINICAL ARTICLE; COLOR; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG URINE LEVEL; EMBOLISM; EMBOLISM PREVENTION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HEMATOLOGY ANALYZER; HUMAN; POINT OF CARE TESTING; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; URINALYSIS; BLOOD; CHEMISTRY; ENZYME ASSAY; LABORATORY; POINT OF CARE SYSTEM; STANDARDS; URINE;

ANTICOAGULANTS; CHROMOGENIC COMPOUNDS; DABIGATRAN; ENZYME ASSAYS; FACTOR XA INHIBITORS; HUMANS; LABORATORIES; POINT-OF-CARE SYSTEMS; PYRAZOLES; PYRIDONES; RIVAROXABAN;

EID: 84955255487     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2015-0389     Document Type: Article

References (33)

1. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. Guidelines-CPG ESCCfP, Document R. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-413.
2. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e419S-94S.
3. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e278S-325S.
4. Skeppholm M, Hjemdahl P, Antovic JP, Muhrbeck J, Eintrei J, Ronquist-Nii Y, et al. On the monitoring of dabigatran treatment in real life patients with atrial fibrillation. Thromb Res 2014;134:783-9.
5. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27.
6. Hapgood G, Butler J, Malan E, Chunilal S, Tran H. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost 2013;110:308-15.
7. Douxfils J, Dogne JM, Mullier F, Chatelain B, Ronquist-Nii Y, Malmstrom RE, et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013;110:543-9.
8. Antovic JP, Skeppholm M, Eintrei J, Boija EE, Soderblom L, Norberg EM, et al. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol 2013;69:1875-81.
9. Harenberg J, Marx S, Erdle S, Kramer R. Determination of the anticoagulant effects of new oral anticoagulants: an unmet need. Expert Rev Hematol 2012;5:107-13.
10. Samama MM, Amiral J, Guinet C, Le Flem L, Seghatchian J. Monitoring plasma levels of factor Xa inhibitors: how, why and when Expert Rev Hematol 2013;6:155-64.
11. Rodgers R, Bagot CN, Lawrence C, Hickman G, McGurk M, Tait RC. Correlating prothrombin time with plasma rivaroxaban level. Br J Haematol 2013;163:685-7.
12. Patel JP, Roberts LN, Chitongo PB, Patel RK, Arya R. More on normal prothrombin times in the presence of therapeutic levels of rivaroxaban-early experience from Kings College Hospital. Br J Haematol 2013;162:717-8.
13. Douxfils J, Tamigniau A, Chatelain B, Chatelain C, Wallemacq P, Dogne JM, et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 2013;110:723-31.
14. Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, et al, Expert group on coagulation of the external quality assurance in laboratory medicine in S. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011;105:371-8.
15. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010;103:815-25.
16. Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 2011; 32:183-7.
17. Harenberg J, Marx S, Weiss C, Kramer R, Samama M, Schulman S. Report of the subcommittee of control of anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost 2012;10:1433-6.
18. Harenberg J, Du S, Weiss C, Kramer R, Hoppensteadt D, Walenga J. Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH. J Thromb Haemost 2014;12:801-4.
19. Jambor C, von Pape KW, Spannagl M, Dietrich W, Giebl A, Weisser H. Multiple electrode whole blood aggregometry, PFA-100, and in vivo bleeding time for the point-of-care assessment of aspirin-induced platelet dysfunction in the preoperative setting. Anesth Analg 2011;113:31-9.
20. Mani H, Herth N, Kasper A, Wendt T, Schuettfort G, Weil Y, et al. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant. Ther Drug Monit 2014;36:624-31.
21. Harenberg J, Kramer S, Du S, Zolfaghari S, Schulze A, Kramer R, et al. Measurement of rivaroxaban and apixaban in serum samples of patients. Eur J Clin Invest 2014;44:743-52.
22. Harenberg J, Kramer S, Du S, Weiss C, Kramer R. Concept of a point of care test to detect new oral anticoagulants in urine samples. Thromb J 2013;11:15.
23. Harenberg J, Giese C, Marx S, Kramer R. Determination of dabigatran in human plasma samples. Semin Thromb Hemost 2012;38:16-22.
24. Harenberg J, Kraemer R. Direct factor Xa inhibitors, International Patent Application PCT/EP2011/005586, 2011.
25. Du S, Weiss C, Giese C, Kraemer S, Wehling M, Kraemer R, et al. Determination of dabigatran in plasma, serum and urine samples: comparison of six methods. Clin Chem Lab Med 2015;53:1237-47.
26. Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. Population pharmacokinetics and pharmacodynamics of once-and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008;100:453-61.
27. van Ryn J, Goss A, Hauel N, Wienen W, Priepke H, Nar H, et al. The discovery of dabigatran etexilate. Front Pharmacol 2013;4:12.
28. Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 2013;76:776-86.
29. Francart SJ, Hawes EM, Deal AM, Adcock DM, Gosselin R, Jeanneret C, et al. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost 2014;111:1133-40.
30. Samama MM, Guinet C, Le Flem L, Ninin E, Debue JM. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. J Thromb Thrombolysis 2013;35:140-6.
31. Harenberg J, Kraemer S, Du S, Giese C, Schulze A, Kraemer R, et al. Determination of direct oral anticoagulants from human serum samples. Semin Thromb Hemost 2014;40:129-34.
32. Du S, Kramer S, Giese C, Weiss C, Wehling M, Kramer R, et al. Chromogenic assays for measurement of rivaroxaban from EDTA anticoagulated plasma samples. Thromb Haemost 2015;113:1149-51.
33. Harenberg J, Du S, Kramer S, Kramer R, Wehling M, Weiss C. Measurement of non-vitamin K antagonist oral anticoagulants in patient plasma using Heptest-STAT coagulation method. Therapeut Drug Monitor 2015;37:375-80.